Late-breaking libtayo® (cemiplimab) pivotal data in advanced non-small cell lung cancer and basal cell carcinoma to be presented at esmo

Cambridge, mass. and tarrytown, n.y.
REGN Ratings Summary
REGN Quant Ranking